Table 5 |
|||||||||
|
Correlation of c-met, Sdc1 and E-cad expression with angiogenic and lymphangiogenic factors |
|||||||||
|
c-met |
E-cad |
Sdc1 |
|||||||
|
|
|||||||||
|
Negative (n = 73) |
Positive (n = 69) |
P |
Negative (n = 48) |
Positive (n = 101) |
P |
Negative (n = 42) |
Positive (n = 105) |
P |
|
|
|
|||||||||
|
VEGF-A |
36.2% |
53.8% |
0.040 |
26.2% |
52.0% |
0.005 |
55% |
41.6% |
0.149 |
|
Flt-1 |
18.6% |
7.7% |
0.063 |
14.3% |
11.5% |
0.642 |
12.8% |
12.5% |
0.959 |
|
KDR |
48.4% |
63.1% |
0.094 |
47.4% |
56.4% |
0.347 |
45.7% |
58.3% |
0.198 |
|
VEGF-C |
84.5% |
94.1% |
0.068 |
80.4% |
91.8% |
0.048 |
80.5% |
91.5% |
0.061 |
|
Flt-4 |
92.9% |
98.6% |
0.099 |
95.1% |
97.0% |
0.584 |
90.0% |
97.2% |
0.071 |
|
ET-1 |
47.7% |
59.7% |
0.176 |
52.4% |
48.9% |
0.709 |
47.4% |
51.6% |
0.661 |
|
ETAR |
56.7% |
92.6% |
<0.001 |
53.8% |
86.9% |
<0.001 |
70.3% |
79.0% |
0.277 |
|
ETBR |
23.4% |
57.4% |
<0.001 |
30.8% |
43.3% |
0.177 |
31.6% |
47.0% |
0.102 |
|
BFGF |
17.4% |
11.9% |
0.394 |
10.0% |
13.4% |
0.583 |
18.9% |
11.4% |
0.250 |
|
FGFR1 |
89.1% |
98.4% |
0.028 |
92.3% |
95.9% |
0.394 |
91.4% |
96.0% |
0.287 |
|
|
|||||||||
|
bFGF, basic fibroblast growth factor; E-cad, E-cadherin; ET, endothelin; ETA/BR, endothelin A/B receptor; FGFR, fibroblast growth factor receptor; Sdc, syndecan; VEGF, vascular endothelial growth factor. |
|||||||||
|
Götte et al. Breast Cancer Research 2007 9:R8 doi:10.1186/bcr1641 |
|||||||||
